|
COVID-19 Scientific Interest Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCCIH, NCI, NEI, NHGRI, NHLBI, NIAID, NIAMS, NICHD, NIDCR, NIDDK, NIEHS, NIMHD, NINDS, OD/DPCPSI/ORWH
|
Scientific interest group discussing science, clinical, epidemiology, and social issues around SARS-CoV-2 and COVID-19. Includes members from FDA. Organizes seminars, workshops, websites, and originally cataloging research and reagents at NIH and FDA intramural programs.
|
|
COVID-19 Testing and Diagnostics Working Group
|
Committee, Work group, Advisory group, or Task Force
|
Not Reported
|
NIBIB
|
The COVID-19 Testing and Diagnostics Working Group (TDWG) develops testing-related guidance and provides targeted investments to expand the available testing supply and maximize testing capacity. Specifically, this group seeks to:Understand the diagnostic supply chain, including projected production and potential constraints and bottlenecksWork with state public health and laboratory leadership, diagnostics manufacturers, and commercial labs throughout the countryProvide technical assistance to leverage existing testing infrastructure and resources based on available testsDistribute certain testing supplies, focusing primarily on point-of-care technologies, to support states' testing goals
|
|
COVID-RADx-UP Working Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCATS, NEI, NIBIB, NICHD
|
The overarching goal of the RADx-UP initiative is to understand the factors associated with disparities in COVID-19 morbidity and mortality and to lay the foundation to reduce disparities for those underserved and vulnerable populations who are disproportionately affected by, have the highest infection rates of, and/or are most at risk for complications or poor outcomes from the COVID-19 pandemic.
|
|
Critical Path for Rare Neurodegenerative Diseases
|
Research Initiative
|
FDA
|
NINDS
|
Critical Path for Rare Neurodegenerative Diseases is a public-private partnership aimed at advancing the understanding of neurodegenerative diseases and supporting the development and regulatory review of treatments for amyotrophic lateral sclerosis (ALS) and other rare neurodegenerative diseases.
|
|
Cross Federal Workgroup on Telehealth
|
Committee, Work group, Advisory group, or Task Force
|
HRSA, AHRQ, CDC, CMS, FDA, HRSA, IHS
|
NIDA
|
The goal of this work group is to develop a coordinated view of what the Federal government is undertaking in telehealth, in an effort to identify possible collaboration mechanisms and share lessons learned across multiple agencies.
|
|
CTAC Ad hoc Strategic Planning Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA
|
NCI
|
The CTAC SPWG was charged to re-assess NCI’s strategic vision for its clinical trials system for 2030 and beyond. The Working Group will review and address the capabilities of the clinical trials infrastructure necessary for achieving this vision as well as consider recommendations for relevant future CTAC activities.
|
|
CTAC ad hoc Working Group on Streamlining Clinical Trials
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI
|
The CTAC Streamlining Clinical Trials Working Group will address the implementation of the CTAC Strategic Planning Working Group’s recommendations around streamlining NCI’s clinical trials. The Working Group will advise NCI on ways to limit data collection in clinical trials as well as optimize the utilization of Electronic Health Records (EHRs) to support clinical trials.*The working group released its interim report in FY2023.
|
|
CURE ID
|
Research Initiative
|
FDA
|
NCATS
|
CURE ID is an internet-based repository that lets the clinical community report novel uses of existing drugs for difficult-to-treat infectious diseases through a website, a smartphone or other mobile device. The platform enables the crowdsourcing of medical information from health care providers to facilitate the development of new treatments for neglected diseases. CURE ID is a collaboration between the FDA and the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). FDA and NIH are also collaborating with the World Health Organization and the Infectious Disease Society of America to assess the global utility of the CURE ID. With an $8.3 million grant from HHS ASPE;s Patient-Centered Outcomes Research Trust Fund, CURE ID is also being expanded to include case reports extracted automatically from electronic health records using the EDGE Tool. This will significantly increase the quantity of data included in CURE ID. The EDGE tool is currently being used for COVID-19 data and is now being expanded to capture data on sepsis and meningitis treatments.
|
|
Cytokine Interest Group
|
Committee, Work group, Advisory group, or Task Force
|
FDA
|
NCI, NEI, NHGRI, NIA, NIAID, NIAMS, NICHD, NIDCD, NIDCR
|
The Cytokine Interest Group brings together NIH and FDA scientists from many different areas working with cytokines as mediators of immune processes. It provides a platform for establishing networks for the exchange of ideas and reagents. Its activities comprise multiple minisymposia throughout the year and an award for the best paper in cytokine research for postdoctoral fellows working at the NIH or FDA.
|
|
DailyMed
|
Resource Development
|
FDA
|
NLM
|
DailyMed provides high-quality information about marketed drugs, including FDA labeling information (package inserts). The website provides health care providers, information professionals, researchers, and the public with a standard, comprehensive, up-to-date, look-up and download resource of medication content and labeling as found in medication package inserts. http://www.dailymed.nlm.nih.gov
|